Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
详细信息 查看全文
- 作者：Kathryn E. Beckermann ; Pradeep C. Jolly ; Ju Y. Kim…
- 关键词：Nivolumab ; PD ; 1 ; Renal medullary carcinoma ; Renal cell carcinoma
- 刊名：Journal for ImmunoTherapy of Cancer
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：5
- 期：1
- 全文大小：775KB
- 刊物主题：Oncology; Immunology;
- 出版者：BioMed Central
- ISSN：2051-1426
- 卷排序：5
文摘
BackgroundRenal medullary carcinoma (RMC) is a rare kidney tumor that occurs in adolescent and young adults, typically in association with sickle cell trait. RMC exhibits rapid disease progression, frequent metastases at diagnosis, and dismal clinical outcomes. Currently available therapies, including cisplatin-based combination chemotherapy, multi-tyrosine kinase, and mTOR inhibitor strategies demonstrate either transient responses or minimal activity. Therefore, further molecular characterization and additional treatment strategies are urgently needed in this aggressive disease. The role of immune system surveillance and responsiveness to anti-PD-1 therapies in RMC are completely unexplored.